Xoma reported $3.4M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agenus USD 16.02M 2.85M Dec/2025
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Ardelyx USD 5.76M 37K Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Curis USD 178K 441K Dec/2023
Eli Lilly USD 114.7M 134.3M Sep/2025
Incyte USD 569K 13K Mar/2026
MacroGenics USD 3.34M 2.54M Sep/2025
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Prothena USD 2.62M 350M Dec/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Xoma USD 3.4M 150K Jun/2024